Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $53
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Price Target Cut to $53.00/Share From $60.00 by Barclays
Tandem Diabetes Care Analyst Ratings
Bernstein Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $25
Bernstein Downgrades Tandem Diabetes Care (TNDM) to a Hold
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $35 to $75
Loss-Making Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Expected To Breakeven In The Medium-Term
Market Cool On Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Revenues Pushing Shares 40% Lower
Express News | Tandem Diabetes Care, Inc. : Wells Fargo Cuts Target Price to $38 From $55
Tandem Diabetes Care (TNDM) Receives a Buy From Barclays
Tandem Diabetes Care: Record Sales and Strategic Growth
Express News | RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $55
Express News | Tandem Diabetes Care Inc : UBS Cuts Target Price to $35 From $40
The Analyst Verdict: Tandem Diabetes Care In The Eyes Of 4 Experts
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $18 to $55
Tandem Diabetes Care Is Maintained at Neutral by Baird
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
Stifel Nicolaus Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Express News | Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $33
Unlock the Full List